Fully human recombinant antibody with neutralizing activity against SARS-Cov-2

March 27, 2020 

The World Health Organization has announced the pandemic of coronavirus infection (COVID-19) that cause the acute respiratory syndrome. Despite the action taken by countries, morbidity and mortality from coronavirus are increasing. Up to sixty percent of people could be infected by a coronavirus in the world. No effective medicines were developed for virus treatment.

ILGEN Inc. will discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. COVID-19 convalescent plasma contains antibodies to the SARS-Cov-2 virus. Using our methodology, the company will isolate antibodies from plasma, determine their structure, and reproduce on a large scale as a recombinant product.